VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the results from the MIDOKIT trial (NCT01830361), which assessed the efficacy of midostaurin in patients with c-KIT or FLT3-ITD mutated t(8;21) acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter